The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1011
ISSUE1011
October 10, 1997
Ardeparin and Danaparoid for Prevention of Deep Vein Thrombosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ardeparin and Danaparoid for Prevention of Deep Vein Thrombosis
October 10, 1997 (Issue: 1011)
Ardeparin sodium (Normiflo - Wyeth-Ayerst), a low-molecular-weight heparin, and danaparoid sodium (Orgaran - Organon), a heparinoid, have been approved by the FDA for prevention of deep vein thrombosis. Without anticoagulation, deep vein thrombosis...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.